Allarity Therapeutics, Inc. Return Tang Equity
Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
- Allarity Therapeutics, Inc. return tang equity for the quarter ending 2026-06-30 was -348.81%, a change of -150.79% year-over-year.
- Allarity Therapeutics, Inc. return tang equity for the quarter ending 2026-03-31 was -162.56%, a change of -37.19% year-over-year.
- Allarity Therapeutics, Inc. return tang equity for the quarter ending 2025-12-31 was -114.28%, a change of 93.29% year-over-year.
- Allarity Therapeutics, Inc. return tang equity for the quarter ending 2025-09-30 was -127.47%, a change of 17.42% year-over-year.
- Allarity Therapeutics, Inc. return tang equity for fiscal 2025 was 26118.60%, a change of 27382.26% from fiscal 2024.
- Allarity Therapeutics, Inc. return tang equity for fiscal 2024 was -1263.66%, a 1440.22% decline from fiscal 2023.
- Allarity Therapeutics, Inc. return tang equity for fiscal 2023 was 94.29%, a 43.27% decline from fiscal 2022.
- Allarity Therapeutics, Inc. return tang equity for fiscal 2022 was 166.20%, a change of 313.00% from fiscal 2021.
- Available history
- 2020-12-31 to 2026-06-30
- Data captured
Historical Return Tang Equity
Annual Return Tang Equity
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |